99216-67-8

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Carbamic acid, [(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, 1,1is used as a precursor in the synthesis of various pharmaceuticals and agrochemicals. Its unique chemical structure allows for the development of new compounds with potential therapeutic and pesticidal properties.
Used in the Production of Carbamate Pesticides:
This carbamic acid derivative is utilized in the production of carbamate pesticides, which are widely used in agriculture to control pests and protect crops. The specific arrangement of functional groups in its structure contributes to the effectiveness of these pesticides.
Used in the Synthesis of Carbamic Acid Esters:
Carbamic acid, [(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, 1,1is also used in the synthesis of carbamic acid esters, which have various applications in chemical and pharmaceutical industries. These esters can be further modified to create new compounds with specific properties and uses.
Used in Medicine and Biotechnology:
Due to its unique chemical structure and properties, Carbamic acid, [(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, 1,1has potential applications in the fields of medicine and biotechnology. It can be used as a building block for the development of new drugs, diagnostic tools, or other bioactive compounds with therapeutic or diagnostic potential.

InChI:InChI=1/C9H19NO4/c1-6(12)7(5-11)10-8(13)14-9(2,3)4/h6-7,11-12H,5H2,1-4H3,(H,10,13)/t6-,7-/m1/s1

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 2592-18-9 Boc-Thr-OH 
• 60538-19-4 N-(tert-butoxycarbonyl)-l-threonine methyl ester 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 98015-52-2 1,2,2,2-Tetrachloroethyl tert-Butyl Carbonate 
• 3228-51-1 L-threoninol 

Downstream Products

• 129396-94-7 tert-butyl N-[(1S,2R)-2-hydroxy-1-(phenylsulfanylmethyl)propyl]carbamate 
• 139374-11-1 (2S,3S)-3-Benzyloxycarbonylamino-2-tert-butoxycarbonylamino-butyric acid 2,2,2-trichloro-ethyl ester 
• 99216-74-7 [(1S,2R)-2,3-Bis-(diphenyl-phosphinoyl)-1-methyl-propyl]-carbamic acid tert-butyl ester 
• 99216-69-0 (2R,3S)-1,2-bis(diphenylphosphino)-3-tBoc-aminobutane 
• 139374-05-3 (2R,3S)-3-(benzyloxycarbonyl)amino-2-(t-butoxycarbonyl)amino-1-(t-butyldimethyl)siloxybutane 
• 139374-07-5 (2S,3S)-3-(benzyloxycarbonylamino)-2-(tert-butoxycarbonylamino)butanoic acid 
• 139374-06-4 (2R,3S)-3-(benzyloxycarbonyl)amino-2-(t-butoxycarbonyl)amino-1-butanol 
• 220542-43-8 6,10-anhydro-7,8,9,11-tetra-O-benzyl-2,4-dideoxy-1,2-N,O-isopropylidene-2-(tert-butoxycarbonylamino)-D-arabino-L-galacto/L-gulo-3-undeculose 
• 213828-84-3 6,10-anhydro-7,8,9,11-tetra-O-benzyl-2,4-dideoxy-1,2-N,O-isopropylidene-2-(tert-butoxycarbonylamino)-D-arabino-D-manno/D-altro-3-undeculose 
• 220542-46-1 (E)-6,10-anhydro-7,8,9,11-tetra-O-benzyl-2,4,5-trideoxy-1,2-N,O-isopropylidene-2-(tert-butoxycarbonylamino)-D-erythro-L-gluco-undec-4-en-3-ulose 
• 220542-62-1 6,10-anhydro-7,8,9,11-tetra-O-benzyl-2,4,5-trideoxy-1,2-N,O-isopropylidene-2-(tert-butoxycarbonylamino)-D-arabino-L-galacto/L-gulo-undecitol 

Relevant academic research and scientific papers

Chiral enantiopure organosilane precursors for the synthesis of periodic mesoporous organosilicas

The manuscript describes synthesis of new chiral organosilica networks starting from modified readily available enantiopure substances such as sugars and amino acids. We report on the successful preparation of robust all-chiral organosilicas by polymerization of the homochiral monomers. When the homochiral organosilane monomers were polymerized in mixtures of polar organic solvents and water in the presence of hydrochloric acid or tetrabutylammonium fluoride as catalysts, mainly spherical microparticles were obtained due to emulsification of the hydrophobic monomers in these mixtures. Polycondensation of the chiral organosilanes in the presence of Pluronic P123 as a template produced ordered mesoporous networks. The new all-chiral materials were characterized by SEM, STEM, BET, SAXS, IR, NMR and TGA.

Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2′s-hydroxy-3′s-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors

A series of terminal nonyl chain and nucleobase modified analogues of (+)-EHNA (III) were synthesized and evaluated for their ability to inhibit adenosine deaminase (ADA). The constrained carbon analogues of (+)-EHNA, 7a-7h, 10a-c, 12, 13, 14 and 17a-c appeared very potent with Ki values in the low nanomolar range. Thio-analogues of (+)-EHNA 24a-e wherein 5′C of nonyl chain replaced by sulfur atom found to be less potent compared to (+)-EHNA. Docking of the representative compounds into the active site of ADA was performed to understand structure-activity relationships. Compounds 7a (Ki: 1.1 nM) 7b (Ki: 5.2 nM) and 26a (Ki: 5.9 nM) showed suitable balance of potency, microsomal stability and demonstrated better pharmacokinetic properties as compared to (+)-EHNA and therefore may have therapeutic potential for various inflammatory diseases, hypertension and cancer.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464

FR901464, a natural product isolated from a bacterium source, activates a reporter gene, inhibits pre-mRNA splicing, and shows antitumor activity. We previously reported the development of a more potent analogue, meayamycin, through the total synthesis of

FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY AND METHOD FOR THEIR PREPARATION

The present invention provides analogs of FR901464, as well as a methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.

SYNTHESIS OF FR901464 AND ANALOGS WITH ANTITUMOR ACTIVITY

The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associ

Diastereoselective synthesis of the acyl side-chain and amino acid (2S,3R)-3-hydroxy-3-methylproline fragments of polyoxypeptin A

Synthesis of the acyl side-chain and amino acid (2S,3R)-3-hydroxy-3- methylproline units of the potent depsipeptide polyoxypeptin A, is described. Key intermediates were secured via diastereoselective addition involving a homoenolate ion and allylation of

Dehydrooligopeptides. XVII. Practical syntheses of all of the diastereomers of N,N-protected 2,3-diaminobutanoic acids from L- and D-threonine derivatives

Syntheses of all of the dioctereomers of 2,3-diaminobutanoic acids, found in some pedtide antibiotics and toxins, were accomplished. The four isomers were derived mainly through two pathways including S(N)2 inversions of the β-substituent of L- or D-threonine derivatives. The various protecting groups and effective nucleophiles for the S(N)2 inversion were examined.

Facile Syntheses of (S,S)-2,3-Diaminobutyric Acid and Acid Containg N-Terminal Tripeptide of Antrimycins

The stereoselective synthesis of (S,S)-2,3-diaminobutyric acid (Dab), which is one of the four uncommon α-amino acid residues of antrimycins (1a) and cirratiomycins (1b), was accomplished.Furthermore, N-terminal tripeptide segment of 1 containing Dab resi